Stockscreener 앱 받기
8.2662
6.19%
0.5162
전일 마감가:
$7.75
열려 있는:
$7.86
하루 거래량:
1.57M
Relative Volume:
1.41
시가총액:
$453.89M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-2.0112
EPS:
-4.11
순현금흐름:
$-86.46M
1주 성능:
+10.32%
1개월 성능:
+43.38%
6개월 성능:
+117.15%
1년 성능:
-29.11%
1일 변동 폭
$7.74
$8.45
1주일 범위
$6.93
$8.45
52주 변동 폭
$2.10
$12.45
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
VSTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
8.26 | 375.36M | 3.64M | -87.37M | -86.46M | -4.11 |
|
ONC
Beigene Ltd Adr
|
236.15 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.07 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.285 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
612.99 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.69 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Tempus partners with Verastem for companion diagnostic development - Yahoo Finance
Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha
Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - BioSpace
(VSTM) Investment Analysis - news.stocktradersdaily.com
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus
Verastem: Q1 Earnings Snapshot - Greenwich Time
Verastem (VSTM) Advances Pipeline with Key Developments | VSTM S - GuruFocus
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem Oncology Reports First Quarter 2025 Financial Results a - GuruFocus
Verastem, Inc. SEC 10-Q Report - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolent Health (EVH), Verastem (VSTM) and Sight Sciences (SGHT) - The Globe and Mail
Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc. - ACCESS Newswire
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased - MSN
Verastem (VSTM) Sees Price Target Increase and FDA Approval Boos - GuruFocus
Verastem (VSTM) Sees Increased Price Target Following FDA Approval | VSTM Stock News - GuruFocus
High-graded low-grade ovarian duo wins for Verastem at FDA - BioWorld MedTech
B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating - marketscreener.com
Verastem (VSTM) Stock Update: Analyst Raises Price Target to $14 | VSTM Stock News - GuruFocus
RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Verastem (VSTM) Price Target Increased by RBC Capital Analyst | VSTM Stock News - GuruFocus
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - BioSpace
Verastem stock price target raised to $19 by Jefferies - Investing.com Canada
Verastem Gains FDA Approval for New Cancer Treatment - TipRanks
Health Care Stocks See Mixed Results In Market Movements - Finimize
Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer - insights.citeline.com
Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer - MedCity News
FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC - Pharmacy Times
US FDA approves Verastem's ovarian cancer therapy - Reuters
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer - Benzinga
US FDA approves Verastem’s cancer therapy - WHTC
Verastem (VSTM) Gains as Analyst Increases Price Target Following FDA Approval | VSTM Stock News - GuruFocus
Verastem Oncology Cancer Drug Combination Gets FDA Approval - marketscreener.com
FDA grants Verastem first approval for rare ovarian cancer treatment - Endpoints News
Verastem Says AVMAPKI FAKZYNJA Co-Pack Expected To Be Available For Adult Patients In U.S. In One Week - marketscreener.com
FDA Greenlights Verastem's (VSTM) New Cancer Treatment - GuruFocus
Verastem's Avmapki Fakzynja receives FDA accelerated approval for ovarian cancer - Seeking Alpha
U.S. FDA approves Verastem's cancer therapy - marketscreener.com
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo - GuruFocus
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo | VSTM Stock News - GuruFocus
Trading (VSTM) With Integrated Risk Controls - news.stocktradersdaily.com
Invesco Ltd. Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
B. Riley Issues Pessimistic Outlook for Verastem Earnings - Defense World
Verastem (VSTM) Schedules Conference Call with Key Executives | - GuruFocus
Verastem Oncology to Present at Upcoming Investor Conferences | - GuruFocus
Ovarian Cancer Market: Epidemiology, Therapies, Companies, - openPR.com
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
2.33%
자본화:
|
볼륨(24시간):